173 related articles for article (PubMed ID: 21672014)
1. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up.
Tylki-Szymanska A; Jurecka A; Zuber Z; Rozdzynska A; Marucha J; Czartoryska B
Acta Paediatr; 2012 Jan; 101(1):e42-7. PubMed ID: 21672014
[TBL] [Abstract][Full Text] [Related]
2. Effects of idursulfase enzyme replacement therapy for Mucopolysaccharidosis type II when started in early infancy: comparison in two siblings.
Tajima G; Sakura N; Kosuga M; Okuyama T; Kobayashi M
Mol Genet Metab; 2013 Mar; 108(3):172-7. PubMed ID: 23375472
[TBL] [Abstract][Full Text] [Related]
3. [Early response to idursulfase in a 31-year old male patient with Hunter syndrome].
Pérez-Calvo J; Bergua Sanclemente I; López Moreno MJ; Torralba Cabeza MÁ; Amores Arriaga B
Rev Clin Esp; 2011; 211(7):e42-5. PubMed ID: 21524741
[TBL] [Abstract][Full Text] [Related]
4. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
[TBL] [Abstract][Full Text] [Related]
5. Early response to idursulfase treatment in a 3 year-old boy affected of Hunter syndrome.
Galán-Gómez E; Guerrero-Rico A; Cáceres-Marzal C; Zambrano-Castaño M; Moreno-Tejero ML; Grande-Tejada AM; Fernández-Hernández S; Vaquerizo-Madrid J; Cardesa-García JJ
Eur J Med Genet; 2008; 51(3):268-71. PubMed ID: 18396123
[TBL] [Abstract][Full Text] [Related]
6. Hunter syndrome: resolution of extensive typical skin lesions after 9 months of enzyme replacement therapy with idursulfase.
Marín LL; Gutiérrez-Solana LG; Fernández AT
Pediatr Dermatol; 2012; 29(3):369-70. PubMed ID: 21995841
[TBL] [Abstract][Full Text] [Related]
7. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up.
Gabrielli O; Clarke LA; Bruni S; Coppa GV
Pediatrics; 2010 Jan; 125(1):e183-7. PubMed ID: 20026495
[TBL] [Abstract][Full Text] [Related]
8. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).
Okuyama T; Tanaka A; Suzuki Y; Ida H; Tanaka T; Cox GF; Eto Y; Orii T
Mol Genet Metab; 2010 Jan; 99(1):18-25. PubMed ID: 19773189
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).
Muenzer J; Gucsavas-Calikoglu M; McCandless SE; Schuetz TJ; Kimura A
Mol Genet Metab; 2007 Mar; 90(3):329-37. PubMed ID: 17185020
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
Wraith JE
Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
[TBL] [Abstract][Full Text] [Related]
11. Hunter disease before and during enzyme replacement therapy.
Hoffmann B; Schulze-Frenking G; Al-Sawaf S; Beck M; Mayatepek E
Pediatr Neurol; 2011 Sep; 45(3):181-4. PubMed ID: 21824567
[TBL] [Abstract][Full Text] [Related]
12. Long-term enzyme replacement therapy in a severe case of mucopolysaccharidosis type II (Hunter syndrome).
Papadia F; Lozupone MS; Gaeta A; Capodiferro D; Lacalendola G
Eur Rev Med Pharmacol Sci; 2011 Mar; 15(3):253-8. PubMed ID: 21528770
[TBL] [Abstract][Full Text] [Related]
13. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.
Garcia AR; DaCosta JM; Pan J; Muenzer J; Lamsa JC
Mol Genet Metab; 2007 Jun; 91(2):183-90. PubMed ID: 17459751
[TBL] [Abstract][Full Text] [Related]
14. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.
Barbier AJ; Bielefeld B; Whiteman DA; Natarajan M; Pano A; Amato DA
Mol Genet Metab; 2013 Nov; 110(3):303-10. PubMed ID: 23988379
[TBL] [Abstract][Full Text] [Related]
15. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS).
Burton BK; Whiteman DA;
Mol Genet Metab; 2011 Jun; 103(2):113-20. PubMed ID: 21439875
[TBL] [Abstract][Full Text] [Related]
16. [Early enzyme replacement therapy - hope for patients with mucopolysaccharidosis Type II].
Orchel-Szastak K; Ptak K; Hrnciar K; Pilch B; Kania U; Bik-Multanowski M
Pediatr Endocrinol Diabetes Metab; 2017; 23(2):111-116. PubMed ID: 29073295
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.
Sohn YB; Cho SY; Lee J; Kwun Y; Huh R; Jin DK
Mol Genet Metab; 2015 Feb; 114(2):156-60. PubMed ID: 25219292
[TBL] [Abstract][Full Text] [Related]
18. [Clinical study of enzyme replacement therapy with idursulfase].
Gutiérrez-Solana LG
Rev Neurol; 2007 Feb; 44 Suppl 1():S7-S11. PubMed ID: 17345556
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Enzyme Replacement Therapy on the range of motion of the upper and lower extremities in 16 Polish patients with mucopolysaccharidosis type II: A long-term follow-up study.
Marucha J; Lipiński P; Tylki-Szymańska A
Acta Biochim Pol; 2022 Feb; 69(1):251-255. PubMed ID: 35226799
[TBL] [Abstract][Full Text] [Related]
20. Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series.
Lampe C; Bosserhoff AK; Burton BK; Giugliani R; de Souza CF; Bittar C; Muschol N; Olson R; Mendelsohn NJ
J Inherit Metab Dis; 2014 Sep; 37(5):823-9. PubMed ID: 24596019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
